Venture capital fundraising by biopharmaceutical companies has been a mixed bag so far in 2023, with a slow start to the year but a relative surge in big financings in March and April. There were only seven $100m-plus VC mega-rounds in January and February combined, but there were seven in March and another seven in April – and last month brought the two largest rounds so far this year.
Hasten Biopharmaceutic Co., Ltd. completed a $315m venture capital round on 20 April and Orbital Therapeutics closed a $270m series A round on 26 April. Abdera Therapeutics Inc. also announced $142m in new financing on 20 April, including a $32m series A and a $110m series B round
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?